Clinical Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patients With Refractory Cirrhotic Ascites

Inclusion Criteria: * Adults \>18 years diagnosed with decompensated liver cirrhosis complicated with ascites grade 2. * Refractory ascites defined as one of the following: 1. Ascites cannot be mobilized despite adherence to low sodium diet of ≤88 mmol/day for ≥1 week and maximum diuretic treatment dose (spironolactone 400 mg/day or furosemide (160 mg/day). 2. Recurrence can't be prevented by medical therapy, Re-appearance of grade 2 or moderate ascites with moderate symmetrical abdominal distention, or grade 3 with massive ascites with marked abdominal distention within 4 weeks of initial mobilization. Exclusion Criteria: * Presenting blood pressure below 90/60 or history of hypotension requires vasopressor treatment. * History of recurrent urinary tract infections, defined by the occurrence of 2 or more acute UTIs within months or 3 within a year. * History of hypersensitivity to SGLT2 inhibitors. * History of diabetic ketoacidosis or presence of risk factors for DKA (i.e alcohol consumption, type 1 diabetes). * Pregnant or lactating women. * History of recurrent episodes of hypoglycemia defined as plasma glucose concentration \<70mg/dL. * Severe renal dysfunction defined as, eGFR \<20 ml/min/1.73m2.